DUSP4 was the only other component of the MEK 6 gene score that was expressed at significantly higher levels in the melanomas of patients who responded to selumetinib and docetaxel, compared with those who progressed at first assessment (Table 1). This evidence concerns the gene MAP2K6 and melanoma.